Citations (170)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Eric Duverger, Guillaume Herlem & Fabien Picaud. (2023) Nanovectorization of Ivermectin to avoid overdose of drugs. Journal of Biomolecular Structure and Dynamics 41:10, pages 4272-4285.
Read now
Read now
Khatereh Zarkesh, Elaheh Entezar-Almahdi, Parisa Ghasemiyeh, Mohsen Akbarian, Marzieh Bahmani, Shahrzad Roudaki, Rahil Fazlinejad, Soliman Mohammadi-Samani, Negar Firouzabadi, Majid Hosseini & Fatemeh Farjadian. (2021) Drug-Based Therapeutic Strategies for COVID-19-Infected Patients and Their Challenges. Future Microbiology 16:18, pages 1415-1451.
Read now
Read now
Mohammad Mahdi Nejadi Babadaei, Anwarul Hasan, Yasaman Vahdani, Samir Haj Bloukh, Majid Sharifi, Ehsan Kachooei, Setareh Haghighat & Mojtaba Falahati. (2021) Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase. Journal of Biomolecular Structure and Dynamics 39:10, pages 3771-3779.
Read now
Read now
Frederick Hansen, Heinz Feldmann & Michael A Jarvis. (2021) Targeting Ebola virus replication through pharmaceutical intervention. Expert Opinion on Investigational Drugs 30:3, pages 201-226.
Read now
Read now
Sara Naghipour, Mahsa Ghodousi, Sara Rahsepar & Sepideh Elyasi. (2020) Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine – from HIV-1 infection to COVID-19. Expert Review of Anti-infective Therapy 18:11, pages 1119-1133.
Read now
Read now
Janie Liang, Rohit K Jangra, Laura Bollinger, Jiro Wada, Sheli R Radoshitzky, Kartik Chandran, Peter B Jahrling, Jens H Kuhn & Kenneth S Jensen. (2017) Candidate Medical Countermeasures Targeting Ebola Virus Cell Entry. Future Virology 12:3, pages 119-140.
Read now
Read now
Sanja Glisic, Slobodan Paessler, Nevena Veljkovic, Vladimir R Perovic, Jelena Prljic & Veljko Veljkovic. (2015) Improving attrition rates in Ebola virus drug discovery. Expert Opinion on Drug Discovery 10:9, pages 1025-1032.
Read now
Read now
Nevena Veljkovic, Jelica Vucicevic, Sabrina Tassini, Sanja Glisic, Veljko Veljkovic & Marco Radi. (2015) Preclinical discovery and development of maraviroc for the treatment of HIV. Expert Opinion on Drug Discovery 10:6, pages 671-684.
Read now
Read now
Articles from other publishers (162)
Jerzy Samolej, Ian J. White, Blair L. Strang & Jason Mercer. (2024) Cardiac glycosides inhibit early and late vaccinia virus protein expression. Journal of General Virology 105:3.
Crossref
Crossref
Mariia S. Bogacheva, Suvi Kuivanen, Swapnil Potdar, Antti Hassinen, Sini Huuskonen, Ina Pöhner, Tamara J. Luck, Laura Turunen, Michaela Feodoroff, Leonora Szirovicza, Kirsi Savijoki, Jani Saarela, Päivi Tammela, Lassi Paavolainen, Antti Poso, Markku Varjosalo, Olli Kallioniemi, Vilja Pietiäinen & Olli Vapalahti. (2024) Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome. Antiviral Research 223, pages 105813.
Crossref
Crossref
Fyaz M.D. Ismail, Lutfun Nahar & Satyajit D. Sarker. 2024. Computational Phytochemistry. Computational Phytochemistry
219
253
.
Sawsan Aboul-Fotouh, Ahmed Nageh Mahmoud, Esraa M. Elnahas, Mohamed Z. Habib & Sahar M. Abdelraouf. (2023) What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms. Virology Journal 20:1.
Crossref
Crossref
Amaresh Mishra, Faizan Abul Qais, Yamini Pathak, Ihosvany Camps & Vishwas Tripathi. (2023) Triamcinolone as a Potential Inhibitor of SARS-CoV-2 Main Protease and
Cytokine Storm: An In silico Study. Letters in Drug Design & Discovery 20:9, pages 1230-1242.
Crossref
Crossref
Nermin S. Ahmed, Heba E. El-Nakib, Marian M. Ramsis, Nouran O. Albably, Jannette Wober, Jan J. Weigand, Kai Schwedtmann, Oliver Zierau & Ashraf H. Abadi. (2023) Structure–Activity Relationships of Triphenylethylene Derivatives and Their Evaluation as Anticancer and Antiviral Agents. ACS Omega 8:29, pages 25903-25923.
Crossref
Crossref
Shuzo Urata, Rokusuke Yoshikawa & Jiro Yasuda. (2023) Calcium Influx Regulates the Replication of Several Negative-Strand RNA Viruses Including Severe Fever with Thrombocytopenia Syndrome Virus. Journal of Virology 97:3.
Crossref
Crossref
Emmanuel Broni, Carolyn Ashley, Joseph Adams, Hammond Manu, Ebenezer Aikins, Mary Okom, Whelton A. MillerIIIIII, Michael D. Wilson & Samuel K. Kwofie. (2023) Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors. International Journal of Molecular Sciences 24:7, pages 6298.
Crossref
Crossref
Deepthi Shankaran, Anjali Singh, Stanzin Dawa, Prabhakar Arumugam, Sheetal Gandotra & Vivek Rao. (2023) The antidepressant sertraline provides a novel host directed therapy module for augmenting TB therapy. eLife 12.
Crossref
Crossref
Harshita Krishnatreyya, Hemanga Hazarika, Bhrigu Kumar Das, Neelutpal Gogoi, Abdul Baquee Ahmed & Kamaruz Zaman. 2023. Viral Drug Delivery Systems. Viral Drug Delivery Systems
161
191
.
Joseph Adams, Kwasi Agyenkwa-Mawuli, Odame Agyapong, Michael D. Wilson & Samuel K. Kwofie. (2022) EBOLApred: A machine learning-based web application for predicting cell entry inhibitors of the Ebola virus. Computational Biology and Chemistry 101, pages 107766.
Crossref
Crossref
Vitória Segabinazzi Foletto, Taciéli Fagundes da Rosa, Marissa Bolson Serafin & Rosmari Hörner. (2022) Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use. European Journal of Clinical Pharmacology 78:10, pages 1601-1611.
Crossref
Crossref
Guojun Sun, Dashun Dong, Zuojun Dong, Qian Zhang, Hui Fang, Chaojun Wang, Shaoya Zhang, Shuaijun Wu, Yichen Dong & Yuehua Wan. (2022) Drug repositioning: A bibliometric analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
Mehdi Eshraghi, Mazaher Ahmadi, Saeid Afshar, Shahrokh Lorzadeh, Aida Adlimoghaddam, Nahid Rezvani Jalal, Ryan West, Sanaz Dastghaib, Somayeh Igder, Seyed Reza Naeimi Torshizi, Amir Mahmoodzadeh, Pooneh Mokarram, Tayyebeh Madrakian, Benedict C. Albensi, Marek J. Łos, Saeid Ghavami & Stevan Pecic. (2022) Enhancing autophagy in Alzheimer's disease through drug repositioning. Pharmacology & Therapeutics 237, pages 108171.
Crossref
Crossref
Esraa ELHADİ, Leena ABDULAZİZ, Ejlal A. A. ABDALLAH, Fadlalbaseer Alamin Eltieb Alnoor ALNOOR & Bashir A. YOUSEF. (2022) Onaylanmış Merkezi Etkili İlaçların Antiviral Aktivitesi: Bir Anlatı İncelemesi. Hacettepe University Journal of the Faculty of Pharmacy.
Crossref
Crossref
Maria Kuzikov, Jannis Woens, Andrea Zaliani, Julia Hambach, Thomas Eden, Boris Fehse, Bernhard Ellinger & Kristoffer Riecken. (2022) High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1. Biomedicine & Pharmacotherapy 151, pages 113104.
Crossref
Crossref
Daniela Iaconis, Licia Bordi, Giulia Matusali, Carmine Talarico, Candida Manelfi, Maria Candida Cesta, Mara Zippoli, Francesca Caccuri, Antonella Bugatti, Alberto Zani, Federica Filippini, Laura Scorzolini, Marco Gobbi, Marten Beeg, Arianna Piotti, Monica Montopoli, Veronica Cocetta, Silvia Bressan, Enrico M. Bucci, Arnaldo Caruso, Emanuele Nicastri, Marcello Allegretti & Andrea R. Beccari. (2022) Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants. Cell Death & Disease 13:5.
Crossref
Crossref
Heather L. Ciallella, Daniel P. Russo, Swati Sharma, Yafan Li, Eddie Sloter, Len Sweet, Heng Huang & Hao Zhu. (2022) Predicting Prenatal Developmental Toxicity Based On the Combination of Chemical Structures and Biological Data. Environmental Science & Technology 56:9, pages 5984-5998.
Crossref
Crossref
Rajashri R. Naik, Ashok K. Shakya, Safwan M. Aladwan & Mohamed El-Tanani. (2022) Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19. Frontiers in Pharmacology 13.
Crossref
Crossref
Ching-Hsuan Liu, Yee-Tung Hu, Shu Hui Wong & Liang-Tzung Lin. (2022) Therapeutic Strategies against Ebola Virus Infection. Viruses 14:3, pages 579.
Crossref
Crossref
Miao Xu, Manisha Pradhan, Kirill Gorshkov, Jennifer D. Petersen, Min Shen, Hui Guo, Wei Zhu, Carleen Klumpp-Thomas, Sam Michael, Misha Itkin, Zina Itkin, Marco R. Straus, Joshua Zimmerberg, Wei Zheng, Gary R. Whittaker & Catherine Z. Chen. (2022) A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry. SLAS Discovery 27:2, pages 86-94.
Crossref
Crossref
Vinicius M. Alves, Daniel Korn, Vera Pervitsky, Andrew Thieme, Stephen J. Capuzzi, Nancy Baker, Rada Chirkova, Sean Ekins, Eugene N. Muratov, Anthony Hickey & Alexander Tropsha. (2022) Knowledge-based approaches to drug discovery for rare diseases. Drug Discovery Today 27:2, pages 490-502.
Crossref
Crossref
Thanigaimalai Pillaiyar & Stefan Laufer. (2021) Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy. Journal of Medicinal Chemistry 65:2, pages 955-982.
Crossref
Crossref
Marcello Allegretti, Maria Candida Cesta, Mara Zippoli, Andrea Beccari, Carmine Talarico, Flavio Mantelli, Enrico M. Bucci, Laura Scorzolini & Emanuele Nicastri. (2021) Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection. Cell Death & Differentiation 29:1, pages 156-166.
Crossref
Crossref
Alloysius Chibuike Ogodo, Ibrahim Alhaji Sabo & Emmanuel Onyemaechi Eze. 2022. Coronavirus Drug Discovery. Coronavirus Drug Discovery
171
189
.
Zeenat A. Shyr, Yu-Shan Cheng & Wei Zheng. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
789
812
.
Ruikun Du, Qinghua Cui, Michael Caffrey & Lijun Rong. 2022. Virus Entry Inhibitors. Virus Entry Inhibitors
155
170
.
B. Mercorelli & A. Loregian. 2021. Antiviral Discovery for Highly Pathogenic Emerging Viruses. Antiviral Discovery for Highly Pathogenic Emerging Viruses
232
255
.
Patrick Iversen, Sandra Bixler, Christopher D. Kane & Travis K. Warren. 2021. Antiviral Discovery for Highly Pathogenic Emerging Viruses. Antiviral Discovery for Highly Pathogenic Emerging Viruses
61
90
.
Joshua Davis, Ugochukwu Umeh & Rand Saba. (2021) Treatment of SARS-CoV-2 (COVID-19): A safety perspective. World Journal of Pharmacology 10:1, pages 1-32.
Crossref
Crossref
Shea R. GoldenDonald L. RosensteinTom BelhornJulie Blatt. (2021) Repurposing Psychotropic Agents for Viral Disorders: Beyond Covid. ASSAY and Drug Development Technologies 19:6, pages 373-385.
Crossref
Crossref
Akanksha Rajput, Anamika Thakur, Amber Rastogi, Shubham Choudhury & Manoj Kumar. (2021) Computational identification of repurposed drugs against viruses causing epidemics and pandemics via drug-target network analysis. Computers in Biology and Medicine 136, pages 104677.
Crossref
Crossref
Mohammad Rafi Khezri, Naime Majidi Zolbanin, Morteza Ghasemnejad-berenji & Reza Jafari. (2021) Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection. European Journal of Pharmacology 905, pages 174191.
Crossref
Crossref
Mathavan Muthaiyan, Leimarembi Devi Naorem, Vassavi Seenappa, Shilpa Sri Pushan & Amouda Venkatesan. (2021) Ebolabase: Zaire ebolavirus-human protein interaction database for drug-repurposing. International Journal of Biological Macromolecules 182, pages 1384-1391.
Crossref
Crossref
Nikita Abramenko, Fréderic Vellieux, Petra Tesařová, Zdeněk Kejík, Robert Kaplánek, Lukáš Lacina, Barbora Dvořánková, Daniel Rösel, Jan Brábek, Adam Tesař, Milan Jakubek & Karel SmetanaJr.Jr.. (2021) Estrogen Receptor Modulators in Viral Infections Such as SARS−CoV−2: Therapeutic Consequences. International Journal of Molecular Sciences 22:12, pages 6551.
Crossref
Crossref
Ruili Huang, Miao Xu, Hu Zhu, Catherine Z. Chen, Wei Zhu, Emily M. Lee, Shihua He, Li Zhang, Jinghua Zhao, Khalida Shamim, Danielle Bougie, Wenwei Huang, Menghang Xia, Mathew D. Hall, Donald Lo, Anton Simeonov, Christopher P. Austin, Xiangguo Qiu, Hengli Tang & Wei Zheng. (2021) Biological activity-based modeling identifies antiviral leads against SARS-CoV-2. Nature Biotechnology 39:6, pages 747-753.
Crossref
Crossref
Xinlei Li & Tao Peng. (2021) Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery. Frontiers in Pharmacology 12.
Crossref
Crossref
Marawan Ahmed, Horia Jalily Hasani, Subha Kalyaanamoorthy & Khaled Barakat. (2021) GPCR_LigandClassify.py; a rigorous machine learning classifier for GPCR targeting compounds. Scientific Reports 11:1.
Crossref
Crossref
Eric Duverger, Guillaume Herlem & Fabien Picaud. (2021) A potential solution to avoid overdose of mixed drugs in the event of Covid-19: Nanomedicine at the heart of the Covid-19 pandemic. Journal of Molecular Graphics and Modelling 104, pages 107834.
Crossref
Crossref
Keiko Imamura, Yasuteru Sakurai, Takako Enami, Ran Shibukawa, Yohei Nishi, Akira Ohta, Tsugumine Shu, Jitsutaro Kawaguchi, Sayaka Okada, Thomas Hoenen, Jiro Yasuda & Haruhisa Inoue. (2021) iPSC screening for drug repurposing identifies anti‐RNA virus agents modulating host cell susceptibility. FEBS Open Bio 11:5, pages 1452-1464.
Crossref
Crossref
Shukur Wasman Smail, Muhammad Saeed, Twana alkasalias, Zhikal Omar Khudhur, Delan Ameen Younus, Mustafa Fahmi Rajab, Wayel Habib Abdulahad, Hafiz Iftikhar Hussain, Kamal Niaz & Muhammad Safdar. (2021) Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review. Food and Chemical Toxicology 150, pages 112087.
Crossref
Crossref
Hu Zhu, Catherine Z. Chen, Srilatha Sakamuru, Jinghua Zhao, Deborah K. Ngan, Anton Simeonov, Mathew D. Hall, Menghang Xia, Wei Zheng & Ruili Huang. (2021) Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics. Scientific Reports 11:1.
Crossref
Crossref
Courtney L. Finch, Julie Dyall, Shuang Xu, Elizabeth A. Nelson, Elena Postnikova, Janie Y. Liang, Huanying Zhou, Lisa Evans DeWald, Craig J. Thomas, Amy Wang, Xin Xu, Emma Hughes, Patrick J. Morris, Jon C. Mirsalis, Linh H. Nguyen, Maria P. Arolfo, Bryan Koci, Michael R. Holbrook, Lisa E. Hensley, Peter B. Jahrling, Connie Schmaljohn, Lisa M. Johansen, Gene G. Olinger, Joshua T. Schiffer & Judith M. White. (2021) Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo. Microorganisms 9:3, pages 566.
Crossref
Crossref
B. Nobile, M. Durand, E. Olié, S. Guillaume, J. P. Molès, E. Haffen & P. Courtet. (2021) The Anti-inflammatory Effect of the Tricyclic Antidepressant Clomipramine and Its High Penetration in the Brain Might Be Useful to Prevent the Psychiatric Consequences of SARS-CoV-2 Infection. Frontiers in Pharmacology 12.
Crossref
Crossref
Adam Schafer, Rui Xiong, Laura Cooper, Raghad Nowar, Hyun Lee, Yangfeng Li, Benjamin E. Ramirez, Norton P. Peet, Michael Caffrey, Gregory R. J. Thatcher, Erica Ollmann Saphire, Han Cheng & Lijun Rong. (2021) Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry. PLOS Pathogens 17:2, pages e1009312.
Crossref
Crossref
Catherine Z. Chen, Paul Shinn, Zina Itkin, Richard T. Eastman, Robert Bostwick, Lynn Rasmussen, Ruili Huang, Min Shen, Xin Hu, Kelli M. Wilson, Brianna M. Brooks, Hui Guo, Tongan Zhao, Carleen Klump-Thomas, Anton Simeonov, Samuel G. Michael, Donald C. Lo, Matthew D. Hall & Wei Zheng. (2021) Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2. Frontiers in Pharmacology 11.
Crossref
Crossref
Mohammad Rejaur Rahman, Anik Banik, Ishtiak Malique Chowdhury, Emran Hossain Sajib & Sanchita Sarkar. (2021) Identification of potential antivirals against SARS-CoV-2 using virtual screening method. Informatics in Medicine Unlocked 23, pages 100531.
Crossref
Crossref
Catherine Z. Chen, Miao Xu, Manisha Pradhan, Kirill Gorshkov, Jennifer D. Petersen, Marco R. Straus, Wei Zhu, Paul Shinn, Hui Guo, Min Shen, Carleen Klumpp-Thomas, Samuel G. Michael, Joshua Zimmerberg, Wei Zheng & Gary R. Whittaker. (2020) Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles. ACS Pharmacology & Translational Science 3:6, pages 1165-1175.
Crossref
Crossref
Ahmed Mostafa, Ahmed Kandeil, Yaseen A. M. M. Elshaier, Omnia Kutkat, Yassmin Moatasim, Adel A. Rashad, Mahmoud Shehata, Mokhtar R. Gomaa, Noura Mahrous, Sara H. Mahmoud, Mohamed GabAllah, Hisham Abbas, Ahmed El Taweel, Ahmed E. Kayed, Mina Nabil Kamel, Mohamed El Sayes, Dina B. Mahmoud, Rabeh El-Shesheny, Ghazi Kayali & Mohamed A. Ali. (2020) FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2. Pharmaceuticals 13:12, pages 443.
Crossref
Crossref
Anil Mathew Tharappel, Subodh Kumar Samrat, Zhong Li & Hongmin Li. (2020) Targeting Crucial Host Factors of SARS-CoV-2. ACS Infectious Diseases 6:11, pages 2844-2865.
Crossref
Crossref
Qi Zhang, Catherine Zhengzheng Chen, Manju Swaroop, Miao Xu, Lihui Wang, Juhyung Lee, Amy Qiu Wang, Manisha Pradhan, Natalie Hagen, Lu Chen, Min Shen, Zhiji Luo, Xin Xu, Yue Xu, Wenwei Huang, Wei Zheng & Yihong Ye. (2020) Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discovery 6:1.
Crossref
Crossref
Mohammed Gaber Mohamed Hamed & Radwa Samir Hagag. (2020) The possible immunoregulatory and anti-inflammatory effects of selective serotonin reuptake inhibitors in coronavirus disease patients. Medical Hypotheses 144, pages 110140.
Crossref
Crossref
Zeenat A. Shyr, Kirill Gorshkov, Catherine Z. Chen & Wei Zheng. (2020) Drug Discovery Strategies for SARS-CoV-2. Journal of Pharmacology and Experimental Therapeutics 375:1, pages 127-138.
Crossref
Crossref
Kristin Vassileva, Mark Marsh & Sandip Patel. (2020) Two-pore channels as master regulators of membrane trafficking and endocytic well-being. Current Opinion in Physiology 17, pages 163-168.
Crossref
Crossref
Maxim V. Kuleshov, Daniel J. Stein, Daniel J.B. Clarke, Eryk Kropiwnicki, Kathleen M. Jagodnik, Alon Bartal, John E. Evangelista, Jason Hom, Minxuan Cheng, Allison Bailey, Abigail Zhou, Laura B. Ferguson, Alexander Lachmann & Avi Ma'ayan. (2020) The COVID-19 Drug and Gene Set Library. Patterns 1:6, pages 100090.
Crossref
Crossref
Yogesh Kumar, Harvijay Singh & Chirag N. Patel. (2020) In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Journal of Infection and Public Health 13:9, pages 1210-1223.
Crossref
Crossref
Chunfeng Li & Genhong Cheng. (2020) Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?. Frontiers in Immunology 11.
Crossref
Crossref
Xuhui Jin, Yuxuan Zhang, Abeer Alharbi, Ali Hanbashi, Ali Alhoshani & John Parrington. (2020) Targeting Two-Pore Channels: Current Progress and Future Challenges. Trends in Pharmacological Sciences 41:8, pages 582-594.
Crossref
Crossref
Bharat Damle, Manoli Vourvahis, Erjian Wang, Joanne Leaney & Brian Corrigan. (2020) Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID‐19. Clinical Pharmacology & Therapeutics 108:2, pages 201-211.
Crossref
Crossref
Nicholas S. Eyre, Emily N. Kirby, Daniel R. Anfiteatro, Gustavo Bracho, Alice G. Russo, Peter A. White, Amanda L. Aloia & Michael R. Beard. (2020) Identification of Estrogen Receptor Modulators as Inhibitors of Flavivirus Infection. Antimicrobial Agents and Chemotherapy 64:8.
Crossref
Crossref
Richard T. Eastman, Jacob S. Roth, Kyle R. Brimacombe, Anton Simeonov, Min Shen, Samarjit Patnaik & Matthew D. Hall. (2020) Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Central Science 6:5, pages 672-683.
Crossref
Crossref
Adam R. Aluisio, Shiromi M. Perera, Derrick Yam, Stephanie Garbern, Jillian L. Peters, Logan Abel, Daniel K. Cho, Dayan Woldemichael, Stephen B. Kennedy, Moses Massaquoi, Foday Sahr, Tao Liu & Adam C. Levine. (2020) Association between treatment with oral third‐generation cephalosporin antibiotics and mortality outcomes in Ebola virus disease: a multinational retrospective cohort study. Tropical Medicine & International Health 25:4, pages 433-441.
Crossref
Crossref
Li Zhang, Shan Lei, Hui Xie, Qianqian Li, Shuo Liu, Qiang Liu, Weijin Huang, Xinyue Xiao & Youchun Wang. (2019) Screening and Identification of Marburg Virus Entry Inhibitors Using Approved Drugs. Virologica Sinica 35:2, pages 235-239.
Crossref
Crossref
Yi-Seul Yoon, Yejin Jang, Thomas Hoenen, Heegwon Shin, Younghoon Lee & Meehyein Kim. (2020) Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles. BMB Reports 53:3, pages 166-171.
Crossref
Crossref
Mathavan Muthaiyan, Shilpa Sri Pushan, Leimarembi Devi Naorem & Amouda Venkatesan. (2020) Understanding of Zaire ebolavirus–human protein interaction for drug repurposing. VirusDisease 31:1, pages 28-37.
Crossref
Crossref
Yongkang Chen, Yuan Li, Xiaohuan Wang & Peng Zou. (2020) Montelukast, an Anti-asthmatic Drug, Inhibits Zika Virus Infection by Disrupting Viral Integrity. Frontiers in Microbiology 10.
Crossref
Crossref
Lisa Evans DeWald, Joshua C. Johnson, Dawn M. Gerhardt, Lisa M. Torzewski, Elena Postnikova, Anna N. Honko, Krisztina Janosko, Louis Huzella, William E. Dowling, Ann E. Eakin, Blaire L. Osborn, Janet Gahagen, Liang Tang, Carol E. Green, Jon C. Mirsalis, Michael R. Holbrook, Peter B. Jahrling, Julie Dyall & Lisa E. Hensley. (2019) In Vivo Activity of Amodiaquine against Ebola Virus Infection. Scientific Reports 9:1.
Crossref
Crossref
Chunfeng Li, Shulong Zu, Yong-Qiang Deng, Dapei Li, Kislay Parvatiyar, Natalie Quanquin, Jingzhe Shang, Nina Sun, Jiaqi Su, Zhenyang Liu, Min Wang, Saba R. Aliyari, Xiao-Feng Li, Aiping Wu, Feng Ma, Yi Shi, Karin Nielsen-Saines, Jae U. Jung, Frank Xiao-Feng Qin, Cheng-Feng Qin & Genhong Cheng. (2019) Azithromycin Protects against Zika Virus Infection by Upregulating Virus-Induced Type I and III Interferon Responses. Antimicrobial Agents and Chemotherapy 63:12.
Crossref
Crossref
Ruili Huang, Hu Zhu, Paul Shinn, Deborah Ngan, Lin Ye, Ashish Thakur, Gurmit Grewal, Tongan Zhao, Noel Southall, Mathew D. Hall, Anton Simeonov & Christopher P. Austin. (2019) The NCATS Pharmaceutical Collection: a 10-year update. Drug Discovery Today 24:12, pages 2341-2349.
Crossref
Crossref
Muhammad Usman Mirza, Michiel Vanmeert, Amjad Ali, Kanzal Iman, Matheus Froeyen & Muhammad Idrees. (2019) Perspectives towards antiviral drug discovery against Ebola virus. Journal of Medical Virology 91:12, pages 2029-2048.
Crossref
Crossref
Lori E. Dodd, Dean Follmann, Michael Proschan, Jing WangDenis MalvyJohan van GriensvenIza CigleneckiPeter W. HorbyRashid Ansumana, Jia-Fu Jiang, Richard T. DaveyH. Clifford Lane & Aurelie Gouel-Cheron. (2019) A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups. Science Translational Medicine 11:520.
Crossref
Crossref
Arthi Venkatesan, Lavanya Ravichandran & J Febin Prabhu Dass. (2019) Computational Drug Design against Ebola Virus Targeting Viral Matrix Protein VP30. Borneo Journal of Pharmacy 2:2, pages 71-81.
Crossref
Crossref
James Schuler & Ram Samudrala. (2019) Fingerprinting CANDO: Increased Accuracy with Structure- and Ligand-Based Shotgun Drug Repurposing. ACS Omega 4:17, pages 17393-17403.
Crossref
Crossref
Michael K. Lo, Jessica R. Spengler, Bobbie Rae Erickson & Christina F. Spiropoulou. 2019. Neglected Tropical Diseases. Neglected Tropical Diseases
49
91
.
Christopher J. Penny, Kristin Vassileva, Archana Jha, Yu Yuan, Xavier Chee, Elizabeth Yates, Michela Mazzon, Bethan S. Kilpatrick, Shmuel Muallem, Mark Marsh, Taufiq Rahman & Sandip Patel. (2019) Mining of Ebola virus entry inhibitors identifies approved drugs as two-pore channel pore blockers. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1866:7, pages 1151-1161.
Crossref
Crossref
Thomas Lane, Manu Anantpadma, Joel S. Freundlich, Robert A. Davey, Peter B. Madrid & Sean Ekins. (2019) The Natural Product Eugenol Is an Inhibitor of the Ebola Virus In Vitro. Pharmaceutical Research 36:7.
Crossref
Crossref
C. E. Hulseberg, L. Fénéant, K. M. Szymańska-de Wijs, N. P. Kessler, E. A. Nelson, C. J. Shoemaker, C. S. Schmaljohn, S. J. Polyak & J. M. White. (2019) Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses. Journal of Virology 93:8.
Crossref
Crossref
Emily M. LeeSteven A. TitusMiao XuHengli TangWei Zheng. (2019) High-Throughput Zika Viral Titer Assay for Rapid Screening of Antiviral Drugs. ASSAY and Drug Development Technologies 17:3, pages 128-139.
Crossref
Crossref
Megan R Edwards & Christopher F Basler. (2019) Current status of small molecule drug development for Ebola virus and other filoviruses. Current Opinion in Virology 35, pages 42-56.
Crossref
Crossref
Faraz Shaikh, Yuguang ZhaoLuis AlvarezMaria IliopoulouChristopher Lohans, Christopher J. Schofield, Sergi Padilla-Parra, Shirley W. I. Siu, Elizabeth E. FryJingshan Ren & David I. Stuart. (2019) Structure-Based in Silico Screening Identifies a Potent Ebolavirus Inhibitor from a Traditional Chinese Medicine Library. Journal of Medicinal Chemistry 62:6, pages 2928-2937.
Crossref
Crossref
Cristiano Salata, Arianna Calistri, Gualtiero Alvisi, Michele Celestino, Cristina Parolin & Giorgio Palù. (2019) Ebola Virus Entry: From Molecular Characterization to Drug Discovery. Viruses 11:3, pages 274.
Crossref
Crossref
Maya A. Farha & Eric D. Brown. (2019) Drug repurposing for antimicrobial discovery. Nature Microbiology 4:4, pages 565-577.
Crossref
Crossref
Helen W. Hernandez, Melinda Soeung, Kimberley M. Zorn, Norah Ashoura, Melina Mottin, Carolina Horta Andrade, Conor R. Caffrey, Jair Lage de Siqueira-Neto & Sean Ekins. (2018) High Throughput and Computational Repurposing for Neglected Diseases. Pharmaceutical Research 36:2.
Crossref
Crossref
Manu Anantpadma, Thomas Lane, Kimberley M. Zorn, Mary A. Lingerfelt, Alex M. Clark, Joel S. Freundlich, Robert A. Davey, Peter B. Madrid & Sean Ekins. (2019) Ebola Virus Bayesian Machine Learning Models Enable New in Vitro Leads. ACS Omega 4:1, pages 2353-2361.
Crossref
Crossref
Elena K. Schneider-Futschik, Daniel Hoyer, Alexander A. Khromykh, Jonathan B. Baell, Glenn A. Marsh, Mark A. Baker, Jian Li & Tony Velkov. (2018) Contemporary Anti-Ebola Drug Discovery Approaches and Platforms. ACS Infectious Diseases 5:1, pages 35-48.
Crossref
Crossref
Moushumee Das, Sangeeta Baro & Sachin Kumar. (2019) Evaluation of imidazole and its derivative against Newcastle disease virus infection in chicken: A drug repurposing approach. Virus Research 260, pages 114-122.
Crossref
Crossref
Života Selaković, Julie P. Tran, Krishna P. Kota, Marija Lazić, Cary Retterer, Robert Besch, Rekha G. Panchal, Veronica Soloveva, Vantongreen A. Sean, Wells B. Jay, Aleksandar Pavić, Tatjana Verbić, Branka Vasiljević, Kathleen Kuehl, Allen J. Duplantier, Sina Bavari, Rajini Mudhasani & Bogdan A. Šolaja. (2019) Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action. European Journal of Medicinal Chemistry 162, pages 32-50.
Crossref
Crossref
Sandeep Sharma & Jeena Gupta. 2019. Pathogenicity and Drug Resistance of Human Pathogens. Pathogenicity and Drug Resistance of Human Pathogens
251
282
.
Mohammed Bule, Fazlullah Khan & Kamal Niaz. 2019. Recent Advances in Animal Virology. Recent Advances in Animal Virology
425
446
.
Aaron Lindstrom, Manu Anantpadma, Logan Baker, N. M. Raghavendra, Robert Davey & Vincent Jo Davisson. (2018)
Phenotypic Prioritization of Diphyllin Derivatives That Block Filoviral Cell Entry by Vacuolar (H
+
)‐ATPase Inhibition
. ChemMedChem 13:24, pages 2664-2676.
Crossref
Crossref
Julie Dyall, Elizabeth A Nelson, Lisa Evans DeWald, Rajarshi Guha, Brit J Hart, Huanying Zhou, Elena Postnikova, James Logue, Walter M Vargas, Robin Gross, Julia Michelotti, Nicole Deiuliis, Richard S Bennett, Ian Crozier, Michael R Holbrook, Patrick J Morris, Carleen Klumpp-Thomas, Crystal McKnight, Tim Mierzwa, Paul Shinn, Pamela J Glass, Lisa M Johansen, Peter B Jahrling, Lisa E Hensley, Gene G OlingerJrJr, Craig Thomas & Judith M White. (2018) Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures. The Journal of Infectious Diseases 218:suppl_5, pages S672-S678.
Crossref
Crossref
Wei Xu, Shuai Xia, Jing Pu, Qian Wang, Peiyu Li, Lu Lu & Shibo Jiang. (2018) The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses. Frontiers in Microbiology 9.
Crossref
Crossref
Daniel P. Martins, Michael Taynnan Barros, Massimiliano Pierobon, Meenakshisundaram Kandhavelu, Pietro Lio & Sasitharan Balasubramaniam. (2018) Computational Models for Trapping Ebola Virus Using Engineered Bacteria. IEEE/ACM Transactions on Computational Biology and Bioinformatics 15:6, pages 2017-2027.
Crossref
Crossref
Beatrice Mercorelli, Giorgio Palù & Arianna Loregian. (2018) Drug Repurposing for Viral Infectious Diseases: How Far Are We?. Trends in Microbiology 26:10, pages 865-876.
Crossref
Crossref
Nakyung Lee, David Shum, Alexander König, Hichul Kim, Jinyeong Heo, Saehong Min, Jihye Lee, Yoonae Ko, Inhee Choi, Honggun Lee, Constantin Radu, Thomas Hoenen, Ji-Young Min & Marc P. Windisch. (2018) High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system. Antiviral Research 158, pages 226-237.
Crossref
Crossref
Kuldeep Dhama, Kumaragurubaran Karthik, Rekha Khandia, Sandip Chakraborty, Ashok Munjal, Shyma K. Latheef, Deepak Kumar, Muthannan Andavar Ramakrishnan, Yashpal Singh Malik, Rajendra Singh, Satya Veer Singh Malik, Raj Kumar Singh & Wanpen Chaicumpa. (2018) Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus. Frontiers in Immunology 9.
Crossref
Crossref
Lizette Elena Leiva-Suero, Jorge Marcelo Morales, Sandra Elizabeth Villacís-Valencia, Milagros Escalona-Rabaza, Graciela De las Mercedes Quishpe-Jara, Elena Vicenta Hernández-Navarro & Miriam Fernández-Nieto. (2018) Ébola, abordaje clínico integral. Revista de la Facultad de Medicina 66:3, pages 293-299.
Crossref
Crossref
Yuguang ZhaoJingshan Ren, Elizabeth E. FryJulia XiaoAlain R. TownsendDavid I. Stuart. (2018) Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs. Journal of Medicinal Chemistry 61:11, pages 4938-4945.
Crossref
Crossref
Shu Yang, Miao Xu, Emily M Lee, Kirill Gorshkov, Sergey A. Shiryaev, Shihua He, Wei Sun, Yu-Shan Cheng, Xin Hu, Anil Mathew Tharappel, Billy Lu, Antonella Pinto, Chen Farhy, Chun-Teng Huang, Zirui Zhang, Wenjun Zhu, Yuying Wu, Yi Zhou, Guang Song, Heng Zhu, Khalida Shamim, Carles Martínez-Romero, Adolfo García-Sastre, Richard A. Preston, Dushyantha T. Jayaweera, Ruili Huang, Wenwei Huang, Menghang Xia, Anton Simeonov, Guoli Ming, Xiangguo Qiu, Alexey V. Terskikh, Hengli Tang, Hongjun Song & Wei Zheng. (2018) Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell Discovery 4:1.
Crossref
Crossref
Veerendra Koppolu & T. Shantha Raju. (2018) Zika virus outbreak: a review of neurological complications, diagnosis, and treatment options. Journal of NeuroVirology 24:3, pages 255-272.
Crossref
Crossref
Jeanne M. Sisk, Matthew B. Frieman & Carolyn E. Machamer. (2018) Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. Journal of General Virology 99:5, pages 619-630.
Crossref
Crossref
Stephen J. Capuzzi, Wei Sun, Eugene N. Muratov, Carles Martínez-Romero, Shihua He, Wenjun Zhu, Hao Li, Gregory Tawa, Ethan G. Fisher, Miao Xu, Paul Shinn, Xiangguo Qiu, Adolfo García-Sastre, Wei Zheng & Alexander Tropsha. (2018) Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors. Journal of Medicinal Chemistry 61:8, pages 3582-3594.
Crossref
Crossref
Qing Chen, Ke Tang, Xiaoyu Zhang, Panpan Chen & Ying Guo. (2018) Establishment of pseudovirus infection mouse models for in vivo pharmacodynamics evaluation of filovirus entry inhibitors. Acta Pharmaceutica Sinica B 8:2, pages 200-208.
Crossref
Crossref
Julie Huiyuan Xiao, Pramila Rijal, Lisa Schimanski, Arun Kumar Tharkeshwar, Edward Wright, Wim Annaert & Alain Townsend. (2018) Characterization of Influenza Virus Pseudotyped with Ebolavirus Glycoprotein. Journal of Virology 92:4.
Crossref
Crossref
Jingshan RenYuguang ZhaoElizabeth E. FryDavid I. Stuart. (2018) Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection. Journal of Medicinal Chemistry 61:3, pages 724-733.
Crossref
Crossref
Wei Zheng, Wei Sun & Anton Simeonov. (2017) Drug repurposing screens and synergistic drug‐combinations for infectious diseases. British Journal of Pharmacology 175:2, pages 181-191.
Crossref
Crossref
Elisa Fanunza, Aldo Frau, Angela Corona & Enzo Tramontano. 2018. Neglected Diseases: Extensive Space for Modern Drug Discovery. Neglected Diseases: Extensive Space for Modern Drug Discovery
135
173
.
Fyaz M.D. Ismail, Lutfun Nahar & Satyajit D. Sarker. 2018. Computational Phytochemistry. Computational Phytochemistry
165
192
.
Farakh Javed, Khanzadi N. Manzoor, Mubashar Ali, Irshad U. Haq, Abid A. Khan, Assad Zaib & Sobia Manzoor. (2017) Zika virus: what we need to know?. Journal of Basic Microbiology 58:1, pages 3-16.
Crossref
Crossref
Runqing Huang, Guohua Zhu, Jing Zhang, Yuxiong Lai, Yu Xu, Jianguo He & Junfeng Xie. (2017) Betanodavirus-like particles enter host cells via clathrin-mediated endocytosis in a cholesterol-, pH- and cytoskeleton-dependent manner. Veterinary Research 48:1.
Crossref
Crossref
Julie Dyall, Robin Gross, Jason Kindrachuk, Reed F. Johnson, Gene G. OlingerJr.Jr., Lisa E. Hensley, Matthew B. Frieman & Peter B. Jahrling. (2017) Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. Drugs 77:18, pages 1935-1966.
Crossref
Crossref
Anupam Banerjee, Abantika Pal, Debnath Pal & Pralay Mitra. (2017) Ebolavirus interferon antagonists—protein interaction perspectives to combat pathogenesis. Briefings in Functional Genomics.
Crossref
Crossref
James Schuler, Matthew Hudson, Diane Schwartz & Ram Samudrala. (2017) A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola Virus Disease Treatment. Molecules 22:10, pages 1777.
Crossref
Crossref
Chunfeng Li, Xingliang Zhu, Xue Ji, Natalie Quanquin, Yong-Qiang Deng, Min Tian, Roghiyh Aliyari, Xiangyang Zuo, Ling Yuan, Shabbir Khan Afridi, Xiao-Feng Li, Jae U. Jung, Karin Nielsen-Saines, Frank Xiao-Feng Qin, Cheng-Feng Qin, Zhiheng Xu & Genhong Cheng. (2017) Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital Microcephaly in Mice. EBioMedicine 24, pages 189-194.
Crossref
Crossref
Kohei Torikai, Rintaro Koga, Xiaohui Liu, Kaoru Umehara, Tatsuya Kitano, Kenji Watanabe, Tohru Oishi, Hiroshi Noguchi & Yasuyuki Shimohigashi. (2017) Design and synthesis of benzoacridines as estrogenic and anti-estrogenic agents. Bioorganic & Medicinal Chemistry 25:20, pages 5216-5237.
Crossref
Crossref
Sandra L. Bixler, Allen J. Duplantier & Sina Bavari. (2017) Discovering Drugs for the Treatment of Ebola Virus. Current Treatment Options in Infectious Diseases 9:3, pages 299-317.
Crossref
Crossref
Ashok Munjal, Rekha Khandia, Kuldeep Dhama, Swati Sachan, Kumaragurubaran Karthik, Ruchi Tiwari, Yashpal S. Malik, Deepak Kumar, Raj K. Singh, Hafiz M. N. Iqbal & Sunil K. Joshi. (2017) Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future Perspectives. Frontiers in Microbiology 8.
Crossref
Crossref
Anna N. Honko, Joshua C. Johnson, Jonathan S. Marchand, Louis Huzella, Ricky D. Adams, Nicholas Oberlander, Lisa M. Torzewski, Richard S. Bennett, Lisa E. Hensley, Peter B. Jahrling & Gene G. Olinger. (2017) High dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus Makona. Scientific Reports 7:1.
Crossref
Crossref
Elizabeth A. Nelson, Julie Dyall, Thomas Hoenen, Alyson B. Barnes, Huanying Zhou, Janie Y. Liang, Julia Michelotti, William H. Dewey, Lisa Evans DeWald, Richard S. Bennett, Patrick J. Morris, Rajarshi Guha, Carleen Klumpp-Thomas, Crystal McKnight, Yu-Chi Chen, Xin Xu, Amy Wang, Emma Hughes, Scott Martin, Craig Thomas, Peter B. Jahrling, Lisa E. Hensley, Gene G. Olinger & Judith M. White. (2017) The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. PLOS Neglected Tropical Diseases 11:4, pages e0005540.
Crossref
Crossref
Haoyang Li, Fei Yu, Shuai Xia, Yufeng Yu, Qian Wang, Ming Lv, Yan Wang, Shibo Jiang & Lu Lu. (2017) Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles. Antimicrobial Agents and Chemotherapy 61:4.
Crossref
Crossref
Kyle C. Arend, Erik M. Lenarcic, Heather A. Vincent, Naim Rashid, Eric Lazear, Ian M. McDonald, Thomas S.K. Gilbert, Michael P. East, Laura E. Herring, Gary L. Johnson, Lee M. Graves & Nathaniel J. Moorman. (2017) Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) Antivirals. Molecular & Cellular Proteomics 16:4, pages S263-S276.
Crossref
Crossref
Hanlu Fan, Xiaohong Du, Jingyuan Zhang, Han Zheng, Xiaohui Lu, Qihui Wu, Haifeng Li, Han Wang, Yi Shi, George Gao, Zhuan Zhou, Dun-Xian Tan & Xiangdong Li. (2017) Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium. Scientific Reports 7:1.
Crossref
Crossref
Hussein Sweiti, Obinna Ekwunife, Thomas Jaschinski & Stefan K. Lhachimi. (2017) Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review. Current Therapeutic Research 84, pages 10-21.
Crossref
Crossref
Wei Sun, Shihua He, Carles Martínez-Romero, Jennifer Kouznetsova, Gregory Tawa, Miao Xu, Paul Shinn, Ethan G. Fisher, Yan Long, Omid Motabar, Shu Yang, Philip E. Sanderson, Peter R. Williamson, Adolfo García-Sastre, Xiangguo Qiu & Wei Zheng. (2017) Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Research 137, pages 165-172.
Crossref
Crossref
Lisa Henß, Simon Beck, Tatjana Weidner, Nadine Biedenkopf, Katja Sliva, Christopher Weber, Stephan Becker & Barbara S. Schnierle. (2016) Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry. Virology Journal 13:1.
Crossref
Crossref
Stephen R. Welch, Lisa Wiggleton Guerrero, Ayan K. Chakrabarti, Laura K. McMullan, Mike Flint, Gregory R. Bluemling, George R. Painter, Stuart T. Nichol, Christina F. Spiropoulou & César G. Albariño. (2016) Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems. Antiviral Research 136, pages 9-18.
Crossref
Crossref
Gaurav Chopra, Sashank Kaushik, Peter Elkin & Ram Samudrala. (2016) Combating Ebola with Repurposed Therapeutics Using the CANDO Platform. Molecules 21:12, pages 1537.
Crossref
Crossref
Baptiste Martin, Thomas Hoenen, Bruno Canard & Etienne Decroly. (2016) Filovirus proteins for antiviral drug discovery: A structure/function analysis of surface glycoproteins and virus entry. Antiviral Research 135, pages 1-14.
Crossref
Crossref
Stuart Dowall, Kevin Bewley, Robert Watson, Seshadri Vasan, Chandradhish Ghosh, Mohini Konai, Gro Gausdal, James Lorens, Jason Long, Wendy Barclay, Isabel Garcia-Dorival, Julian Hiscox, Andrew Bosworth, Irene Taylor, Linda Easterbrook, James Pitman, Sian Summers, Jenny Chan-Pensley, Simon Funnell, Julia Vipond, Sue Charlton, Jayanta Haldar, Roger Hewson & Miles Carroll. (2016) Antiviral Screening of Multiple Compounds against Ebola Virus. Viruses 8:11, pages 277.
Crossref
Crossref
Muhammad Mirza & Nazia Ikram. (2016) Integrated Computational Approach for Virtual Hit Identification against Ebola Viral Proteins VP35 and VP40. International Journal of Molecular Sciences 17:11, pages 1748.
Crossref
Crossref
Christopher M. Coleman, Jeanne M. Sisk, Rebecca M. Mingo, Elizabeth A. Nelson, Judith M. White & Matthew B. Frieman. (2016) Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. Journal of Virology 90:19, pages 8924-8933.
Crossref
Crossref
Miao Xu, Emily M Lee, Zhexing Wen, Yichen Cheng, Wei-Kai Huang, Xuyu Qian, Julia TCW, Jennifer Kouznetsova, Sarah C Ogden, Christy Hammack, Fadi Jacob, Ha Nam Nguyen, Misha Itkin, Catherine Hanna, Paul Shinn, Chase Allen, Samuel G Michael, Anton Simeonov, Wenwei Huang, Kimberly M Christian, Alison Goate, Kristen J Brennand, Ruili Huang, Menghang Xia, Guo-li Ming, Wei Zheng, Hongjun Song & Hengli Tang. (2016) Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nature Medicine 22:10, pages 1101-1107.
Crossref
Crossref
Ming Ni, Chen Chen, Jun Qian, Hai-Xia Xiao, Wei-Feng Shi, Yang Luo, Hai-Yin Wang, Zhen Li, Jun Wu, Pei-Song Xu, Su-Hong Chen, Gary Wong, Yuhai Bi, Zhi-Ping Xia, Wei Li, Hui-jun Lu, Juncai Ma, Yi-Gang Tong, Hui Zeng, Sheng-Qi Wang, George F. Gao, Xiao-Chen Bo & Di Liu. (2016) Intra-host dynamics of Ebola virus during 2014. Nature Microbiology 1:11.
Crossref
Crossref
Elizabeth Nelson, Alyson Barnes, Ronald Wiehle, Gregory Fontenot, Thomas Hoenen & Judith White. (2016) Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications. Viruses 8:8, pages 206.
Crossref
Crossref
Manu Anantpadma, Jennifer Kouznetsova, Hang Wang, Ruili Huang, Andrey Kolokoltsov, Rajarshi Guha, Aaron R. Lindstrom, Olena Shtanko, Anton Simeonov, David J. Maloney, Wendy Maury, Douglas J. LaCount, Ajit Jadhav & Robert A. Davey. (2016) Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors. Antimicrobial Agents and Chemotherapy 60:8, pages 4471-4481.
Crossref
Crossref
Wei Sun, Philip E. Sanderson & Wei Zheng. (2016) Drug combination therapy increases successful drug repositioning. Drug Discovery Today 21:7, pages 1189-1195.
Crossref
Crossref
Daniel Jones & Sergi Padilla-Parra. (2016) The β-Lactamase Assay: Harnessing a FRET Biosensor to Analyse Viral Fusion Mechanisms. Sensors 16:7, pages 950.
Crossref
Crossref
Jourdan A. Andersson, Eric C. Fitts, Michelle L. Kirtley, Duraisamy Ponnusamy, Alex G. Peniche, Sara M. Dann, Vladimir L. Motin, Sadhana Chauhan, Jason A. Rosenzweig, Jian Sha & Ashok K. Chopra. (2016) New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria. Antimicrobial Agents and Chemotherapy 60:6, pages 3717-3729.
Crossref
Crossref
A.M. Baldé, M.S. Traoré, M.A. Baldé, M.S. Barry, A. Diallo, M. Camara, S. Traoré, M. Kouyaté, S. Traoré, S. Ouo-Ouo, A.L. Myanthé, N. Keita, N.L. Haba, K. Goumou, F. Bah, A. Camara, M.S.T. Diallo, M. Sylla, E.S. Baldé, S. Diané, L. Pieters & K. Oularé. (2016) Ethnomedical and ethnobotanical investigations on the response capacities of Guinean traditional health practioners in the management of outbreaks of infectious diseases: The case of the Ebola virus epidemic. Journal of Ethnopharmacology 182, pages 137-149.
Crossref
Crossref
Celine Deffrasnes, Glenn A. Marsh, Chwan Hong Foo, Christina L. Rootes, Cathryn M. Gould, Julian Grusovin, Paul Monaghan, Michael K. Lo, S. Mark Tompkins, Timothy E. Adams, John W. Lowenthal, Kaylene J. Simpson, Cameron R. Stewart, Andrew G. D. Bean & Lin-Fa Wang. (2016) Genome-wide siRNA Screening at Biosafety Level 4 Reveals a Crucial Role for Fibrillarin in Henipavirus Infection. PLOS Pathogens 12:3, pages e1005478.
Crossref
Crossref
Aleksandar Antanasijevic, Carolyn Kingsley, Arnab Basu, Terry L. Bowlin, Lijun Rong & Michael Caffrey. (2016) Application of virus-like particles (VLP) to NMR characterization of viral membrane protein interactions. Journal of Biomolecular NMR 64:3, pages 255-265.
Crossref
Crossref
Scott M Berry, Elizabeth A Petzold, Peter Dull, Nathan M Thielman, Coleen K Cunningham, G Ralph Corey, Micah T McClain, David L Hoover, James Russell, J McLeod Griffiss & Christopher W Woods. (2016) A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response. Clinical Trials 13:1, pages 22-30.
Crossref
Crossref
Qi Liu, Yuxiao Zhang, Wenwen Jing, Sixiu Liu, Dawei Zhang & Guodong Sui. (2016) First airborne pathogen direct analysis system. The Analyst 141:5, pages 1637-1640.
Crossref
Crossref
Yizhuo Wang, Rui Cui, Guiming Li, Qianqian Gao, Shilin Yuan, Ralf Altmeyer & Gang Zou. (2016) Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Antiviral Research 125, pages 1-7.
Crossref
Crossref
Stuart D. Dowall, Andrew Bosworth, Robert Watson, Kevin Bewley, Irene Taylor, Emma Rayner, Laura Hunter, Geoff Pearson, Linda Easterbrook, James Pitman, Roger Hewson & Miles W. Carroll. (2015) Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. Journal of General Virology 96:12, pages 3484-3492.
Crossref
Crossref
Zlatko Janeba. (2015) Development of Small‐Molecule Antivirals for Ebola. Medicinal Research Reviews 35:6, pages 1175-1194.
Crossref
Crossref
Forrest Keck, Pouya Ataey, Moushimi Amaya, Charles Bailey & Aarthi Narayanan. (2015) Phosphorylation of Single Stranded RNA Virus Proteins and Potential for Novel Therapeutic Strategies. Viruses 7:10, pages 5257-5273.
Crossref
Crossref
Han Cheng, Calli M. Lear-Rooney, Lisa Johansen, Elizabeth Varhegyi, Zheng W. Chen, Gene G. Olinger & Lijun Rong. (2015) Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists. Journal of Virology 89:19, pages 9932-9938.
Crossref
Crossref
Jeanne M. Sisk & Matthew B. Frieman. (2015) Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens. ACS Infectious Diseases 1:9, pages 401-402.
Crossref
Crossref
Života Selaković, Veronica Soloveva, Dima N. Gharaibeh, Jay Wells, Sandra Šegan, Rekha G. Panchal & Bogdan A. Šolaja. (2015) Anti-Ebola Activity of Diazachrysene Small Molecules. ACS Infectious Diseases 1:6, pages 264-271.
Crossref
Crossref
Sean Ekins, Joel S. Freundlich, Alex M. Clark, Manu Anantpadma, Robert A. Davey & Peter Madrid. (2017) Machine learning models identify molecules active against the Ebola virus in vitro. F1000Research 4, pages 1091.
Crossref
Crossref
Sean Ekins, Joel S. Freundlich, Alex M. Clark, Manu Anantpadma, Robert A. Davey & Peter Madrid. (2016) Machine learning models identify molecules active against the Ebola virus in vitro. F1000Research 4, pages 1091.
Crossref
Crossref
Sean Ekins, Joel S. Freundlich, Alex M. Clark, Manu Anantpadma, Robert A. Davey & Peter Madrid. (2015) Machine learning models identify molecules active against the Ebola virus in vitro. F1000Research 4, pages 1091.
Crossref
Crossref
Veljko Veljkovic, Marco Goeijenbier, Sanja Glisic, Nevena Veljkovic, Vladimir R. Perovic, Milan Sencanski, Donald R. Branch & Slobodan Paessler. (2015) In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease. F1000Research 4, pages 104.
Crossref
Crossref
Sean Ekins & Megan Coffee. (2015) FDA approved drugs as potential Ebola treatments. F1000Research 4, pages 48.
Crossref
Crossref
Sean Ekins & Megan Coffee. (2015) FDA approved drugs as potential Ebola treatments. F1000Research 4, pages 48.
Crossref
Crossref
Nadia Litterman, Christopher Lipinski & Sean Ekins. (2015) Small molecules with antiviral activity against the Ebola virus. F1000Research 4, pages 38.
Crossref
Crossref
Veljko Veljkovic, Philippe M. Loiseau, Bruno Figadere, Sanja Glisic, Nevena Veljkovic, Vladimir R. Perovic, David P. Cavanaugh & Donald R. Branch. (2015) Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Research 4, pages 34.
Crossref
Crossref
Veljko Veljkovic, Philippe M. Loiseau, Bruno Figadere, Sanja Glisic, Nevena Veljkovic, Vladimir R. Perovic, David P. Cavanaugh & Donald R. Branch. (2015) Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Research 4, pages 34.
Crossref
Crossref
Jason Long, Edward Wright, Eleonora Molesti, Nigel Temperton & Wendy Barclay. (2015) Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Research 4, pages 30.
Crossref
Crossref
Jason Long, Edward Wright, Eleonora Molesti, Nigel Temperton & Wendy Barclay. (2015) Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Research 4, pages 30.
Crossref
Crossref
Gayatri Ramakrishnan, Nagasuma R. Chandra & Narayanaswamy Srinivasan. (2015) Recognizing drug targets using evolutionary information: implications for repurposing FDA-approved drugs against Mycobacterium tuberculosis H37Rv. Molecular BioSystems 11:12, pages 3316-3331.
Crossref
Crossref